The SSO2 therapy system is intended for use in acute anterior myocardial infarction patients following percutaneous coronary intervention (PCI) performed within 6 hours of symptom onset. The system delivers supersaturated oxygen mixed with the patient’s own blood to the left anterior descending coronary artery, with the goal of further reducing infarct size.

If you have a Hayes login, click here to view the full report on the Knowledge Center.